Aduro Biotech | Engineered Immunotherapy for Cancer

STING Pathway:

Using a Tumor’s Composition to Activate an Immune Response

B-select Antibodies:

Modulating Cancer Immunity

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight cancer

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2017 Annual Report

Recent News

December 03, 2018 Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition

November 09, 2018 Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas

November 06, 2018 Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?